QCG
BCRX icon

Quadrant Capital Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quadrant Capital Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-705
Closed -$6.71K – 1396
2026
Q1 		$6.71K Hold
705
– – ﹤0.01% 2297
2025
Q4 		$5.5K Hold
705
– – ﹤0.01% 2348
2025
Q3 		$5.35K Buy
+705
New +$5.87K ﹤0.01% 2311
2025
Q2 		– Sell
-529
Closed -$3.97K – 1478
2025
Q1 		$3.97K Hold
529
– – ﹤0.01% 2400
2024
Q4 		$3.98K Hold
529
– – ﹤0.01% 2359
2024
Q3 		$4.02K Hold
529
– – ﹤0.01% 2364
2024
Q2 		$3.27K Sell
529
-156
-23% -$861 ﹤0.01% 2393
2024
Q1 		$3.48K Buy
685
+22
+3% +$124 ﹤0.01% 2401
2023
Q4 		$3.97K Buy
663
+330
+99% +$1.91K ﹤0.01% 2336
2023
Q3 		$2.36K Buy
+333
New +$2.39K ﹤0.01% 2350
2023
Q2 		– Sell
-211
Closed -$1.76K – 2696
2023
Q1 		$1.76K Buy
+211
New +$2.03K ﹤0.01% 2449

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Quadrant Capital Group's BCRX Position: Q2 2026 in Review

Quadrant Capital Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 705 shares — an estimated $6.71K sold.

Quadrant Capital Group first reported a position in BCRX in Q1 2023 and held it in 11 quarters. The position peaked at $6.71K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Quadrant Capital Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 705 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $6.71K.
  • Quadrant Capital Group first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 11 quarters.
  • Quadrant Capital Group's BioCryst Pharmaceuticals position peaked at $6.71K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.